Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.